TVM Capital Life Science (TVM), a leading international venture capital firm focused on investments in life sciences innovation, announced an investment of up to $25 million in the newly formed U.S.-based biotechnology company, LAmAb Biologics (LAmAb), with its fund TVM Life Science Innovation II SCSp (TVM LSI II).
TVM will provide strategic advice to the company, with Sascha Berger, general partner joining the board of directors and Marc Rivière, serving as a board observer.
